

Arnoud J Templeton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2800708/publications.pdf>

Version: 2024-02-01

88
papers

6,716
citations

126708

33
h-index

64668

79
g-index

89
all docs

89
docs citations

89
times ranked

11805
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. <i>British Journal of Cancer</i> , 2022, 126, 1140-1144.	2.9	23
2	Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. <i>European Urology Open Science</i> , 2022, 40, 16-18.	0.2	6
3	Clinical benefit of cancer drugs approved in Switzerland 2010â€“2019. <i>PLoS ONE</i> , 2022, 17, e0268545.	1.1	2
4	Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6571-6571.	0.8	0
5	Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 117-125.	2.3	4
6	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , 2021, 28, 107-114.	0.9	10
7	Associations between safety, tolerability, and toxicity and the reporting of healthâ€related quality of life in phase III randomized trials in common solid tumors. <i>Cancer Medicine</i> , 2020, 9, 7888-7895.	1.3	5
8	Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0233768.	1.1	6
9	Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. <i>Journal of Clinical Oncology</i> , 2020, 38, 1651-1654.	0.8	50
10	Informative censoring â€” a neglected cause of bias in oncology trials. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 327-328.	12.5	43
11	Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7052-7052.	0.8	0
12	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019, 24, 1188-1194.	1.9	32
13	Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 448-455.	2.6	10
14	Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)â€”SAKK 96/12 (REDUSE).. <i>Journal of Clinical Oncology</i> , 2019, 37, 139-139.	0.8	9
15	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018, 110, 486-492.	3.0	70
16	Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e277-e287.	0.9	4
17	Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 62, 1-8.	3.4	69
18	Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer. <i>Future Science OA</i> , 2018, 4, FSO253.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. <i>Radiation Oncology</i> , 2018, 13, 216.	1.2	46
20	Vitamin D levels in Swiss breast cancer survivors. <i>Swiss Medical Weekly</i> , 2018, 148, w14576.	0.8	4
21	Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. <i>Oncotarget</i> , 2018, 9, 15061-15067.	0.8	2
22	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 145, 584-594.	0.6	85
23	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 337-343.	1.6	4
24	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. <i>Cancer Treatment Reviews</i> , 2017, 56, 1-7.	3.4	42
25	Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. <i>Experimental and Molecular Pathology</i> , 2017, 102, 455-474.	0.9	17
26	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 60, 53-59.	3.4	21
27	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 59, 46-53.	3.4	2
28	Neutrophils in cancer: prognostic role and therapeutic strategies. <i>Molecular Cancer</i> , 2017, 16, 137.	7.9	295
29	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research</i> , 2017, 19, 2.	2.2	457
30	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 2299-2305.	0.8	241
31	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18336-e18336.	0.8	1
32	Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5022-5022.	0.8	0
33	A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16003-e16003.	0.8	0
34	Study of testosterone-guided androgen deprivation therapy in management of prostate cancer. <i>Prostate</i> , 2016, 76, 235-242.	1.2	2
35	Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. <i>International Journal of Cancer</i> , 2016, 138, 671-678.	2.3	56
36	Relevance of randomised controlled trials in oncology. <i>Lancet Oncology</i> , The, 2016, 17, e560-e567.	5.1	74

#	ARTICLE	IF	CITATIONS
37	Under-reporting of harm in clinical trials. <i>Lancet Oncology</i> , The, 2016, 17, e209-e219.	5.1	76
38	The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. <i>Cancer Medicine</i> , 2016, 5, 2792-2799.	1.3	72
39	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. <i>British Journal of Cancer</i> , 2016, 114, 207-212.	2.9	53
40	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 1-8.	1.1	10
41	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016, 70, 358-364.	0.9	133
42	Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration. <i>JAMA Oncology</i> , 2016, 2, 744.	3.4	17
43	Circulating DNA and Survival in Solid Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 399-406.	1.1	30
44	Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. <i>European Urology</i> , 2016, 69, 980-983.	0.9	12
45	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2016, 11, e0154789.	1.1	31
46	<i>In silico</i> analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. <i>Oncotarget</i> , 2016, 7, 22865-22872.	0.8	21
47	Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 839-843.	1.0	6
48	Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2015, 33, 100-106.	0.8	47
49	Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. <i>Journal of Geriatric Oncology</i> , 2015, 6, 23-28.	0.5	24
50	Influence of censoring on conclusions of trials for women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 721-724.	1.3	16
51	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. <i>European Urology</i> , 2015, 68, 506-515.	0.9	41
52	Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2015, 67, 740-749.	0.9	166
53	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015, 6, 39538-39549.	0.8	27
54	Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e95219.	1.1	140

#	ARTICLE	IF	CITATIONS
55	Raising Concern About the American Society of Clinical Oncology Conflict of Interest Policy Amendment. <i>Journal of Clinical Oncology</i> , 2014, 32, 3197-3197.	0.8	2
56	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> , 2014, 120, 3346-3352.	2.0	128
57	Use and Misuse of Waterfall Plots. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	19
58	Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. <i>Prostate</i> , 2014, 74, 1462-1464.	1.2	3
59	Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Oncology Research and Treatment</i> , 2014, 37, 772-776.	0.8	23
60	Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). <i>Breast</i> , 2014, 23, 244-249.	0.9	17
61	Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. <i>Journal of Neuro-Oncology</i> , 2014, 117, 147-152.	1.4	83
62	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 1048-1055.	3.4	34
63	Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt319-djt319.	3.0	279
64	Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1204-1212.	1.1	519
65	Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 317-324.	0.9	60
66	Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). <i>European Urology</i> , 2014, 66, 468-474.	0.9	100
67	Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 235-244.	1.1	73
68	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju124.	3.0	2,202
69	Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5077-5077.	0.8	1
70	Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6550-6550.	0.8	1
71	Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 159-159.	0.8	8
72	Neutrophil to lymphocyte ratio and response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 477-477.	0.8	3

#	ARTICLE	IF	CITATIONS
73	Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 61-61.	0.8	2
74	A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 70-70.	0.8	3
75	Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e88238.	1.1	51
76	Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 43-43.	0.8	0
77	Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 547-547.	0.8	0
78	Effect of multifocality and multicentricity on outcome in early breast cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 546-546.	0.8	2
79	Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5047-5047.	0.8	0
80	Benefit and Harms of New Anti-Cancer Drugs. <i>Current Oncology Reports</i> , 2013, 15, 270-275.	1.8	30
81	Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08). <i>European Urology</i> , 2013, 64, 150-158.	0.9	120
82	Neutrophil/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4130-4130.	0.8	1
83	Management of small HER2 overexpressing tumours. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 289-293.	1.1	14
84	Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome. <i>European Urology</i> , 2011, 60, 1235-1243.	0.9	49
85	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3342-3347.	3.3	175
86	Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1760-1770.	3.0	77
87	Prostatic Metastasis of Renal Cell Carcinoma Successfully Treated with Sunitinib. <i>Urologia Internationalis</i> , 2009, 83, 122-124.	0.6	9
88	Concordant colon tumors in monozygotic twins previously treated for prostate cancer. <i>Familial Cancer</i> , 2009, 8, 167-171.	0.9	5